Revvity, Inc. (RVTY) Stock Analysis

28.0/100
Strong Sell Not Halal Healthcare
Price $154.39
Market Cap $17.24B
52-Week Change +65.30%

Is RVTY a good investment?

Revvity, Inc. (RVTY) has a Plutrex AI rating of 28.0/100 as of November 09, 2026, indicating a Strong Sell consensus. The stock is not classified as halal-compliant. Key strength: Balance sheet fortress: D/E of 0.38 (38.9% below industry average 0.62), FCF of $592M nearly matching total cash of $593M, providing zero near-term distress risk and strategic flexibility. Main concern: Extreme valuation disconnect: P/E of 68.67x (+77.9% above industry 38.62x) and PEG of 7.70 (+50.8% above industry 5.11) for a company growing revenue at 4.3% vs. industry 15.88% — the inverse relationship between premium valuation and below-average growth is the core risk; even analysts consensus target of $150.00 implies -3.3% downside from current price.

Investment Summary

RVTY remains a structurally overvalued stock with deteriorating fundamentals relative to its valuation. At $155.11, the stock trades at a P/E of 68.67x — a 77.9% premium to the industry average of 38.62x — while delivering forward EPS growth of only 8.9% (5-year) and revenue growth of just 4.3%. The PEG ratio of 7.70 (industry average 5.11) confirms investors are paying 7.7x the company's growth rate. ROE of 3.46% is catastrophically below the industry average of 10.89% and below the risk-free rate. The analyst consensus target of $150.00 implies -3.3% downside from current levels, meaning even sell-side optimists see the stock as overvalued. The only bright spots are strong FCF of $592M, conservative D/E of 0.38 vs. industry 0.62, and excellent news sentiment (97/100) driven by Q3 2026 beats. However, positive news cannot justify a 68x earnings multiple for a 4.3% revenue grower — the math simply does not work. Prior rating of 30/100 is confirmed with marginal improvement to 28/100 reflecting modest valuation multiple compression (P/E: 75.4x → 68.67x, PEG: 8.86 → 7.70) offset by continued structural growth underperformance vs. peers.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
65/100
Growth Potential
18/100
Valuation
10/100
Profitability
38/100
Debt Management
82/100
Analyst Sentiment
38/100
Technical Momentum
42/100
Insider Confidence
45/100
News Sentiment
90/100

Fundamental Analysis

RVTY's fundamentals remain deeply problematic at current prices. Valuation: P/E of 68.67x vs. industry 38.62x (+77.9% premium); PEG of 7.70 vs. industry 5.11 (+50.8% premium); P/B of 2.39x on ROE of 3.46% (should be near 1.0x by Gordon Growth logic). Growth: Revenue growth of 4.3% vs. industry 15.88% (-72.9% gap); forward EPS growth of 9.86% next year vs. industry 15.89% (-37.9%); 5-year EPS CAGR of 8.92% vs. industry 12.73% (-29.9%). Profitability: Gross margin of 48.0% (above industry 41.75% — genuine strength); operating margin of 17.1% (essentially in line with industry 17.22% despite gross margin advantage, indicating elevated opex); net margin of 8.63% vs. industry 11.73% (-26.4%); ROE of 3.46% vs. industry 10.89% (-68.2% — most damning relative metric). Health: D/E of 0.38 vs. industry 0.62 (conservative, genuine positive); FCF of $592M nearly matching cash balance of $593M (strong cash conversion); but low ROE questions productive deployment of that capital. At $155.11, applying a growth-fair P/E of 18-22x to forward earnings implies 65-75% downside. FCF-based valuation: $592M FCF × 12x multiple ≈ $7.1B enterprise value implies significant downside from current market cap.

News Sentiment

Revvity is delivering the goods operationally — but Wall Street's reaction is muted, and for good reason. The life sciences and diagnostics company posted a strong Q3 2026, beating both earnings and revenue estimates according to multiple reports including 'Revvity (RVTY) Tops Q3 Earnings and Revenue Estimates' and 'RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up.' The company even raised its full-year 2026 guidance, a signal management has confidence in continued momentum. The Life Sciences segment was called out as a key growth driver in the quarterly results, and the company is seeing expanding interest in AI-related research tools — a hot narrative that helped fuel investor enthusiasm. The 'Revvity Launches Signals LabGistics' product, which connects R&D-to-manufacturing workflows, addresses what management describes as a critical operational gap in the life sciences industry. Even the headline 'Revvity Faced Off With Elevated Investor Expectations — And Won' acknowledges the company cleared a high bar set by the market. Here's the problem: good news is already priced in — and then some. The stock trades at nearly 69 times earnings while growing revenue at just 4% per year. The beat was real, the AI story is intriguing, but no quarterly earnings win changes the fundamental math of paying premium prices for below-average growth. For long-term investors, patience waiting for a better entry point is the only rational play.

Risk Assessment

PRIMARY RISK: Valuation compression is the dominant risk. At 68.67x earnings for 8.9% growth, any earnings miss, guidance cut, or sector multiple compression could trigger 20-40% drawdowns. The stock has already declined from $158.77 to $155.11 (-2.3%) despite exceptional news sentiment, suggesting valuation ceiling is in effect. SECONDARY RISK: Revenue growth of 4.3% vs. industry 15.88% means RVTY is losing market share in a growing sector — if the diagnostics/life sciences market accelerates and RVTY cannot keep pace, relative underperformance compounds. MITIGATION: The strong balance sheet (D/E 0.38, $593M cash) limits bankruptcy/distress risk — this is not a zero scenario. FCF of $592M gives management flexibility for buybacks that could support EPS growth mechanically. UPSIDE RISK (to sell thesis): If AI/software revenue from Signals LabGistics accelerates meaningfully above the 9% forward EPS growth baked in, or if a strategic acquirer bids for the company given the balance sheet quality and gross margin profile, the thesis could be challenged. However, at 68x earnings, even a 15% EPS growth rate would only justify ~25-30x P/E under normal conditions — implying ~55% downside to fair value.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is RVTY a halal stock?

No, Revvity, Inc. (RVTY) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for RVTY?

Revvity, Inc. (RVTY) has a Plutrex AI rating of 28.0/100 with a Strong Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is RVTY a good investment?

According to Plutrex AI, RVTY has a Strong Sell rating (28.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in RVTY?

US stocks like RVTY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in RVTY?

Plutrex AI identifies the main risks for RVTY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about RVTY

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open RVTY in ElBarake